Deals this week: Aldeyra Therapeutics, Oncology Venture Sweden, Treos Bio
US-based biotechnology company Aldeyra Therapeutics has announced a public offering of shares of its common stock to raise funds required primarily for the continued development of its lead compound, ADX-102, and other product candidates.
Part of the raised proceeds will also be used for conducting research and development (R&D), and towards working capital and other general corporate purposes.
Oncology Venture Sweden has announced a rights offering to raise Skr52.89m ($5.92m) in gross proceeds.
The offering includes up to 1.2 million shares of the company’s common stock at a price of Skr45 ($5.04) a share.
The proceeds from the offering will be used for multiple purposes including the in-licensing and the development of an anti-cancer oral tyrosine kinase inhibitor, and for securing the rights for three products for development in women’s cancers from 2X Oncology.
Part of the proceeds will also be used to produce LiPlaCis for the clinical studies in accordance with the agreement signed with Cadila Pharma.
Based in Denmark, Oncology Venture Sweden is a company focused on the R&D of anti-cancer drugs.
UK-based precision cancer immunotherapies developer Treos Bio has completed a financing round participated by a group of private investors.
The company has raised $8m from the round, proceeds from which are intended to be used for conducting the early stage human clinical trial of PolyPEPI, an immunotherapy cancer vaccine being developed by the company for colorectal cancer.
Swiss company Novimmune and South Korean pharmaceutical company LegoChem Biosciences will jointly evaluate an antibody drug conjugate candidate (ADC), under a research agreement signed between the two.
ADCs, unlike chemotherapy, target only cancer cells, while healthy cells are spared.